Cancer clinical trials in the region Centre-Val de Loire
59 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Phase 2
CLL & Richter's syndrome
#NCT06588478
CLL (Chronic Lymphocytic Leukemia)
1
2
3 or more
Targeted therapy
Systemic Treatment-Naive
Centre Hospitalier Régional Universitaire de Tours (Tours)
Loxo Oncology
Phase 2
Lymphoma
#NCT06588478
B cell lymphoma
Lymphocytic lymphoma
None
1
2
3 or more
Targeted therapy
Systemic Treatment-Naive
Centre Hospitalier Régional Universitaire de Tours (Tours)
Loxo Oncology
Phase 2
Endometrial cancer
#NCT03624244
Other
Locally Advanced
Metastatic
None
Surgery
Hormone therapy
Centre Hospitalier Régional Universitaire de Tours (Tours)
Centre Léon Bérard
Phase 2
Lymphoma
#NCT06806033
B cell lymphoma
Large B cell lymphoma
None
Treated / Controled
1
2
3 or more
Systemic Treatment-Naive
Bispecific T-cell engager antibodies
Allogeneic stem cell transplant
Centre Hospitalier Régional Universitaire de Tours (Tours)
Hoffmann-La Roche
Phase 2
Colon cancer
Rectal cancer
#NCT04262687
Metastatic
MSS
None
1
Systemic Treatment-Naive
Surgery
Chemotherapy
MSI/dMMR
Immunotherapy
Immunotherapy
Polyclinique de Blois (La Chaussée-Saint-Victor), Centre Hospitalier Régional Universitaire de Tours (Tours)
Fédération Francophone de Cancérologie Digestive
Phase 2
Lymphoma
#NCT04802590
B cell lymphoma
Mantel cell lymphoma
None
CD20
> 60 ml/min
50-60 ml/min
None
Systemic Treatment-Naive
Centre Hospitalier Régional Universitaire de Tours (Tours)
The Lymphoma Academic Research Organisation (LYSARC)
Phase 2
Prostate cancer
#NCT05826509
Adenocarcinoma
Localized
None
Systemic Treatment-Naive
Systemic Treatment-Naive
Centre Hospitalier Régional Universitaire de Tours (Tours)
Institut Claudius Regaud
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
ALK
EGFR
Bristol-Myers Squibb
Early Access
Lymphoma
B cell lymphoma
Large B cell lymphoma
2
3 or more
Systemic Treatment-Naive
Abbvie
Early Access
Lymphoma
B cell lymphoma
Large B cell lymphoma
2
3 or more
Systemic Treatment-Naive
Hoffmann-La Roche